Strand Therapeutics Names Kunal Bhatia as Chief Financial Officer
Strand Therapeutics, a clinical-stage biotechnology company focused on advancing programmable mRNA medicines, has announced the appointment of Kunal Bhatia as its new Chief Financial Officer. The move comes at a pivotal moment for the company as it transitions from early clinical validation to broader pipeline expansion and long-term strategic growth.
Mr. Bhatia brings approximately 15 years of experience in investment banking within the healthcare and life sciences sectors. Over the course of his career, he has played a key role in advising and executing fundraising initiatives, business development strategies, and mergers and acquisitions for more than 100 public and private biopharmaceutical companies. His appointment reflects Strand Therapeutics’ intention to strengthen its financial leadership as it scales its operations and advances its pipeline of innovative therapies.
Strand Therapeutics has been building a reputation for its work in programmable mRNA technology, an emerging field that seeks to design RNA-based medicines capable of precisely controlling protein expression within the body. This approach holds promise across multiple therapeutic areas, including immuno-oncology, systemic drug delivery, and next-generation in vivo cell therapies. The company’s platform is designed to improve the specificity and safety of treatments, particularly in complex diseases such as cancer.
According to Jake Becraft, Co-founder and Chief Executive Officer of Strand Therapeutics, the company has reached an important inflection point. With early clinical validation already achieved, Strand is now focused on expanding its pipeline and translating its platform into multiple therapeutic programs. Becraft emphasized that the selection of a Chief Financial Officer was a strategic priority, noting that the company sought a leader capable of matching its ambition and sustaining its growth momentum.
He highlighted Mr. Bhatia’s extensive experience working alongside high-growth biotechnology companies, particularly during critical phases such as capital raising and corporate transactions. This background, Becraft noted, positions Bhatia to effectively guide Strand through the complexities of scaling a platform-based biotech company, including navigating investor relations, securing funding, and supporting strategic partnerships.
Before joining Strand Therapeutics, Mr. Bhatia served as interim Chief Financial Officer and Chief Business Officer for a portfolio of private life sciences companies. In these roles, he was responsible for overseeing financial strategy, corporate development, and operational execution, helping organizations prepare for growth and potential market transitions.
Earlier in his career, Bhatia held a senior leadership position as Managing Director in the Healthcare Investment Banking Group at Cowen, where he contributed significantly to the expansion of the firm’s life sciences franchise. His work at Cowen involved advising biotech and pharmaceutical companies on a range of financial transactions, including equity and debt offerings, strategic partnerships, and M&A deals. Prior to that, he gained additional investment banking experience at Jefferies and Credit Suisse, further building his expertise in the healthcare sector.
In commenting on his new role, Mr. Bhatia described Strand Therapeutics as a company at a transformative stage, characterized by strong clinical momentum, an expanding pipeline, and a supportive investor base. He noted that the company’s investor syndicate reflects a high level of confidence in its platform and long-term potential. Bhatia expressed enthusiasm about working with the leadership team to build on this foundation and help guide the company through its next phase of development.
The appointment follows a series of notable corporate and clinical milestones achieved by Strand Therapeutics over the past year. Among these is the successful completion of a $153 million Series B financing round, led by Kinnevik, with participation from prominent investors including Regeneron Ventures, Amgen Ventures, and Eli Lilly. This substantial funding has provided the company with the resources needed to advance its clinical programs and further develop its technology platform.
In addition to its financing achievements, Strand has strengthened its leadership structure with multiple executive and board-level appointments, reinforcing its organizational capabilities as it moves into a more advanced stage of development. The company has also reported initial Phase 1 clinical data for its lead program, STX-001, which is being evaluated in patients with advanced solid tumors who have exhausted existing treatment options. Early findings from this study represent an important step in validating the potential of Strand’s programmable mRNA approach in oncology.
Looking ahead, Strand Therapeutics is preparing for the clinical entry of another key candidate, STX-003, which is expected to begin mid-2026. The company continues to expand its pipeline across multiple modalities and disease indications, leveraging its platform to explore new therapeutic possibilities. This includes efforts to address unmet needs in oncology and beyond, where precision-targeted therapies could offer meaningful improvements over existing treatments.
Mr. Bhatia’s appointment as Chief Financial Officer is expected to play a crucial role in supporting these ambitions. His combined experience in finance, strategy, and business development positions him to help the company navigate the challenges of growth, including capital allocation, investor engagement, and strategic partnerships. As Strand Therapeutics continues to advance its programs and broaden its impact, strong financial leadership will be essential to sustaining its trajectory.
Overall, the addition of Kunal Bhatia to the executive team underscores Strand Therapeutics’ commitment to building a robust organizational foundation capable of supporting long-term innovation. With a growing pipeline, validated platform technology, and increasing investor confidence, the company appears well-positioned to continue its progress in the rapidly evolving field of mRNA therapeutics.
About Strand Therapeutics
Strand Therapeutics is a clinical-stage biotechnology company pioneering programmable mRNA therapeutics to unlock the full potential of genetic medicines. Strand is applying its proprietary Signal Stack platform, which integrates EverScript circular RNA, AmpliScript self-replicating RNA, SignalPath targeted delivery, and logic-driven SignalLock genetic circuits to enable precise control of therapeutic activity across tissues and cell types and overcome foundational limitations in targeting, durability, and safety.
Strand is advancing a pipeline with an initial focus on oncology and autoimmune disease. Its initial program, STX-001, an intratumorally delivered LNP-encapsulated self-replicating RNA expressing IL-12, has demonstrated preliminary evidence of systemic immune activation and anti-tumor activity in patients with advanced solid tumors who have progressed on prior therapies. Building on this early clinical validation, intravenously delivered STX-003 is designed for tumor-targeted expression and avoidance of off-target expression.
STX-003, which is expected to enter the clinic in mid-2026, has the potential to be a major step forward for the fields of genetic medicine and oncology. Strand is also advancing STX-005, an in vivo CAR-T program designed to enable controlled, durable expression and repeat dosing. Founded by MIT synthetic biology pioneers, Strand has raised over $250 million and is headquartered in Boston, MA.
Source Link:https://www.businesswire.com/
